Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data for their combination with a wide range of established and novel anticancer agents and discusses the mechanisms that underpin these interactions.

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 99; no. 5; pp. 689 - 694
Main Authors Nolan, L, Johnson, P W M, Ganesan, A, Packham, G, Crabb, S J
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 02.09.2008
Nature Publishing Group
Subjects
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer Research
Cancer therapies
Cyclin-dependent kinases
Cytotoxicity
DNA methylation
Drug Resistance
Enzyme Inhibitors - administration & dosage
Enzyme Inhibitors - therapeutic use
Enzymes
Epidemiology
Epigenetics
Gene expression
Histone Deacetylase Inhibitors
Humans
Kinases
Medical research
Medical sciences
Melanoma
mini-review
Minireview
Molecular Medicine
Neoplasms - drug therapy
Oncology
Tumors
United Kingdom > UK
inhibitor
combination therapy
histone deacetylase
histone deacetylase; inhibitor
Histone deacetylase
Histone deacetylase inhibitor
Combined treatment
Cancerology
Online AccessGet full text

Cover

More Information
Summary:Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data for their combination with a wide range of established and novel anticancer agents and discusses the mechanisms that underpin these interactions.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6604557